Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Kiniksa Pharmaceuticals International, plc’s reported figures.
Plus components not separately reported this period.
The source filing: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed July 28, 2026. Open the filing →
- Filed
- Jul 28, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-087545
FAQ
- What is Kiniksa Pharmaceuticals International, plc's EBIT?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported EBIT of $27.19M in Q2 2026.
- How has Kiniksa Pharmaceuticals International, plc's EBIT changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's EBIT increased by 34.9% year-over-year, from $20.16M to $27.19M.
- What is the long-term trend for Kiniksa Pharmaceuticals International, plc's EBIT?
- Over 4 years (2021 to 2025), Kiniksa Pharmaceuticals International, plc's EBIT has grown at a -16.2% compound annual growth rate (CAGR), from -$156.64M to $77.22M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Kiniksa Pharmaceuticals International, plc's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude